Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma

NCT07700979 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

900

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric / Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: Cadonilimab
DRUG: CAPOX regimen
DRUG: Nivolumab
DRUG: Placebo

Sponsor

Akeso